DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

GS-5745

Phase Two

Phase Two

Therapeutic Approach

Anti-Inflammatory

GS-5745 is an antibody that may help reduce inflammation in the lungs, leading to improved lung function in people with CF.

Status

A Phase 2 study to test the effectiveness of GS-5745 in adults with CF was stopped in 2017. The decision to discontinue was not due to any safety concerns in the study.

NO FURTHER CLINICAL DEVELOPMENT IN CF IS PLANNED AT THIS TIME. 

Sponsor

This program was sponsored by Gilead. It was conducted within the Cysti Fibrosis Foundation's Therapeutics Development Network.

Contact us about GS-5745 >